AD Scientific Index
 Open Nav
Login Login Pricing & Plans Pricing & Plans
Sandhya Girish

Sandhya Girish

Gilead Sciences Inc. - California / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4381710
-
person_outline Sandhya Girish's MOST POPULAR ARTICLES
1-) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer after prior HER2 … Journal of Clinical Oncology 29 (4), 398-405, 2011
2-) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer J Clin Oncol 28 (16), 2698-2704, 2010
3-) Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2–positive cancer Clinical Cancer Research 17 (20), 6437-6447, 2011
4-) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who were previously treated with … Journal of clinical oncology 30 (26), 3234-3241, 2012
5-) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer Cancer chemotherapy and pharmacology 69 (5), 1229-1240, 2012